<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995978</url>
  </required_header>
  <id_info>
    <org_study_id>31991</org_study_id>
    <nct_id>NCT04995978</nct_id>
  </id_info>
  <brief_title>Insulin Resistance and Androgen Deprivation Therapy</brief_title>
  <official_title>Insulin Resistance in Men With Prostate Cancer on Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most common malignancy amongst men in United States. Androgen&#xD;
      deprivation therapy (ADT) with long acting gonadotropin releasing hormone agonists is&#xD;
      routinely used as adjuvant therapy in intermediate and high risk localized or locally&#xD;
      advanced prostate cancer. Since ADT induces insulin resistance and diabetes, it is important&#xD;
      that cellular and molecular effects of ADT are investigated to define precisely the&#xD;
      mechanisms involved in the pathogenesis of insulin resistance. Pioglitazone, a known insulin&#xD;
      sensitizer, may provide amelioration of insulin resistance in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to conduct a prospective, randomized, double-blind, placebo-controlled&#xD;
      trial in 44 men with nonmetastatic prostate cancer who are receiving ADT with long acting&#xD;
      GnRH agonist (study group). Study subjects will undergo insulin clamp, subcutaneous fat&#xD;
      biopsy, muscle biopsy, have a blood sample taken and fibroscan performed prior to&#xD;
      randomization of study drug. They will then be randomized to 30 mg pioglitazone or placebo&#xD;
      tablet daily for 6 months. Blood samples will be drawn 2 and 4 months following the&#xD;
      initiation of the study drug. The final study visit will be at 6 months. Subjects will&#xD;
      undergo clamp, fat biopsy, muscle biopsy, blood sampling, fibroscan and will be discharged&#xD;
      from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint of the study is to detect a difference in insulin sensitivity as measured by whole body glucose uptake during clamps after treatment with pioglitazone as compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin signaling (Insulin receptor substrate expression in fat tissue)</measure>
    <time_frame>6 months</time_frame>
    <description>A secondary endpoint for the study will be comparison of the relative change from baseline in insulin signaling after pioglitazone or placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 30 mg</intervention_name>
    <description>Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.&#xD;
For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo tablet</intervention_name>
    <description>Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer, non-metastatic&#xD;
&#xD;
          -  Have been on ADT with long acting GnRH agonist continuously for last 3 months, AND&#xD;
             planning to continue ADT for at least 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Used pioglitazone in last 6 months&#xD;
&#xD;
          -  Heart Failure NYHA Class 3 or 4&#xD;
&#xD;
          -  Known to have osteoporosis at this time.&#xD;
&#xD;
          -  history of bladder cancer&#xD;
&#xD;
          -  Hemoglobin &lt;8 g/dl&#xD;
&#xD;
          -  eGFR &lt;15 ml/min/1.73m2&#xD;
&#xD;
          -  liver enzymes (ALT or AST) &gt;3 times the upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandeep Dhindsa, MD</last_name>
    <phone>13149774911</phone>
    <email>sandhindsa@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Campbell, RN</last_name>
    <phone>314-977-9350</phone>
    <email>bobby.campbell@health.slu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis Univeristy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Campbell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Sandeep Singh Dhindsa, M.D., F.A.C.E</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

